These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Other 2016-001485-29 Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Breast... not-yet-due
Exempt, with results 2016-001583-11 Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy 2019-02-22 not-yet-due
Reported results 2016-004466-26 Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy 2020-02-28 due-trials
Listed as ongoing, but also has a completion date 2016-004611-13 Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy Fase 1b/2a studie naar de ve... 2021-10-04 bad-data
Reported results 2017-000358-20 Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer 2020-10-29 due-trials
Other 2019-003826-25 PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer not-yet-due
Other 2020-004930-39 A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic... not-yet-due
Completed, report not yet due Terminated 2021-000186-32 A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRES... 2022-02-02 not-yet-due
Ongoing 2021-000205-24 A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metasta... not-yet-due